Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PYC Therapeutics Limited (AU:PYC)
ASX:PYC
RESEARCH TOOLSreports
Holding AU:PYC?
Track your performance easily
PYC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.15
Previous CloseAU$0.15
Volume200.64K
Average Volume (3M)3.20M
Market Cap
AU$648.44M
Enterprise ValueAU$621.12M
Total Cash (Recent Filing)AU$29.11M
Total Debt (Recent Filing)AU$943.77K
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Feb 27, 2025EPS Estimate
>-AU$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume2,965,570
30 Day Avg. Volume3,201,821
Standard Deviation0.16
R-Squared0.00786
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)26.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside78.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PYC Therapeutics Limited News
PremiumCompany Announcements
FDA Nods PYC Therapeutics’ Eye Disease Drug
PremiumCompany Announcements
PYC Therapeutics Shares Q3 Business Insights
PremiumCompany Announcements
PYC Therapeutics: Income Up, Losses Widen
PremiumCompany Announcements
PYC Therapeutics to Share 2024 Milestones
PremiumCompany Announcements
PYC Therapeutics Begins Clinical Trials for Eye DiseasePremiumCompany Announcements
PYC Therapeutics Presents at Growth ConferencePremiumCompany Announcements
PYC Therapeutics’ VP-001 Shows Vision Improvement
PremiumCompany Announcements
PYC Therapeutics Corrects Clinical Trial DataOptions Prices
Currently, No data available
---
Ownership Overview
43.73% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
56.27% Public Companies and
Individual Investors
PYC FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
Currently, no data Available
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Feb 27, 2025 which is in 161 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Aug 27, 2024. The company reported -AU$0.004 earnings per share for the quarter, beating the consensus estimate of -AU$0.007 by AU$0.003.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is >-AU$0.01.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 4,471,976,600 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, beating expectations of -AU$0.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PYC
---
PYC Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.25 (78.57% Upside)
AU$0.25 (78.57% Upside)
Blogger Sentiment
Bullish
AU:PYC Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.63%
12-Months-Change
Fundamentals
Return on Equity
-69.70%
Trailing 12-Months
Asset Growth
145.49%
Trailing 12-Months
Company Description
PYC Therapeutics Limited
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the major challenge in RNA therapeutics - safe and effective delivery of the drug inside the cell. Geographically, it operates only in Australia.
---
PYC Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(78.57% Upside)
Technical Analysis
Race Oncology Ltd.
―
Botanix Pharmaceuticals Limited
―
Arovella Therapeutics Limited
―
Best Analysts Covering PYC
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+48.03%
reiterated a buy rating 3 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.03% per trade.
---